Multiple Sclerosis

The AJMC® Multiple Sclerosis compendium is a comprehensive resource for clinical news and expert insights for the disabling disease that impacts the brain and spinal cord.

Latest News

Ocrelizumab is approved as an IV infusion for relapsing and primary progressive forms of MS and as a subcutaneous injection, given twice a year. | Image credit: Trsakaoe - stock.adobe.com
Real-World Discontinuations of Ocrelizumab in MS Comparable to Pivotal Trials

January 9th 2025

Data from a systematic review of 30 real-world studies show comparable discontinuation rates of ocrelizumab to those in pivotal clinical trials among patients with different types of multiple sclerosis (MS).

Ocrelizumab is a monoclonal antibody that targets CD20 on B cells | image credit: molekuul.be - stock.adobe.com
Subcutaneous Ocrelizumab Well Tolerated in Patients With MS

January 8th 2025

Patients with MS had higher odds of filling prescriptions for anticonvulsants and higher odds of filling gabapentinoids and gabapentinoids without other anticonvulsants in the years leading up to onset of MS. | Image credit: Vitalii Vodolazskyi - stock.adobe.com
Pain May Be Indicator of MS Prior to Disease Onset: Study

January 6th 2025

Better understanding the vascular sequelae of MS may similarly unlock predictive insights for people with MS, according to investigators. | Image credit: Elena - stock.adobe.com
Meta-Analysis: Vascular Function Worse in People With MS

January 3rd 2025

Top 5 Most-Viewed MS Content of 2024
Top 5 Most-Viewed MS Content of 2024

December 27th 2024

Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis

This video series provides an in-depth look at multiple sclerosis, covering its impact, pathophysiology, treatment strategies, unmet needs, patient satisfaction, and future research. Gain key insights into managing and understanding this condition.

This video series provides an in-depth look at multiple sclerosis, covering its impact, pathophysiology, treatment strategies, unmet needs, patient satisfaction, and future research. Gain valuable insights into managing and understanding this complex condition.
Continuing Medical Education
View All
January 23rd 2025

Exploring Transthyretin-Mediated Amyloidosis and Its Phenotypes: A Comprehensive Approach to Patient Treatment

1.5 Credits / Cardiology, Neurology, Rare Diseases
January 23rd 2025

The Role of the Specialty Pharmacist in Optimizing Treatment for Amyotrophic Lateral Sclerosis: The Impact of Early Intervention, Patient-Centered Care, and Disease-Modifying Therapies in Slowing Disease Progression

1.0 Credit / Neurology
January 23rd 2025

Advancing Targeted Therapies Aimed at Smoldering Disease in Multiple Sclerosis

1.0 Credit / Immunology, Neurology
January 23rd 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
January 23rd 2025

Overview and Burden of Migraine

0.5 Credit / Neurology
January 23rd 2025

The Evolving Treatment Landscape of Migraine

0.5 Credit / Neurology
January 23rd 2025

The Role of the Pharmacist Migraine Management

0.5 Credit / Neurology

More News

Generic Medications in MS Management
July 15th 2021

Generic Medications in MS Management

Neil Minkoff, MD Maria Lopes, MD, MS Nancy Ross, PharmD, BCACP, MSCS, CSP Thomas Leist, MD Darin Okuda, MD
Key opinion leaders in MS describe the impact of generic medication availability on the management of MS and cost of MS treatment.
stethoscope on US flag
July 14th 2021

Greater DMT Adherence Linked With Superior Outcomes Among Veterans With MS

Gianna Melillo
Results of a retrospective observational study indicate good adherence to disease-modifying therapies (DMTs) for multiple sclerosis (MS) is associated with better outcomes among veterans with the disease.
Puzzle-piece picture of spinal column
July 10th 2021

SCS Likely Effective Therapy Among Persons Living With MS

Maggie L. Shaw
Spinal cord stimulation (SCS) to treat pain in persons with multiple sclerosis (MS) was the focus of a recent literature review out of Italy.
Neon-enhanced firing neurons
July 7th 2021

MS Wrap-up: Pregnant Women With MS, ORATORIO Trial Results, and More

AJMC Staff
Here are some of the latest developments in multiple sclerosis (MS) from our sister publication, NeurologyLive®.
Risks of Undertreatment in MS and Impact of Early High Efficacy Therapy
July 6th 2021

Risks of Undertreatment in MS and Impact of Early High Efficacy Therapy

Neil Minkoff, MD Maria Lopes, MD, MS Nancy Ross, PharmD, BCACP, MSCS, CSP Thomas Leist, MD Darin Okuda, MD
Darin Okuda, MD discusses the risk of undertreating MS patients and the avoidance of undertreatment with newer high-efficacy therapies.
Evaluation of MS Outcomes: Patient Clinical Picture
July 6th 2021

Evaluation of MS Outcomes: Patient Clinical Picture

Neil Minkoff, MD Maria Lopes, MD, MS Nancy Ross, PharmD, BCACP, MSCS, CSP Thomas Leist, MD Darin Okuda, MD
MS specialist Thomas Leist, MD provides insights into the challenges of evaluating and monitoring patients with MS.
Treatment Approach in MS Center of Excellence
July 1st 2021

Treatment Approach in MS Center of Excellence

Neil Minkoff, MD Maria Lopes, MD, MS Nancy Ross, PharmD, BCACP, MSCS, CSP Thomas Leist, MD Darin Okuda, MD
Nancy Ross, PharmD, BCACP, MSCS, CSP describes treatment approach and patient navigation in an MS center of excellence.
Payer Management of MS
July 1st 2021

Payer Management of MS

Neil Minkoff, MD Maria Lopes, MD, MS Nancy Ross, PharmD, BCACP, MSCS, CSP Thomas Leist, MD Darin Okuda, MD
Maria Lopes, MD, MS discusses payer considerations and challenges in MS treatment management with the ongoing paradigm shift toward early high-efficacy treatment.
Damaged nerve cells
July 1st 2021

Network Damage Predictive of MS Disease Course, Study Finds

Jared Kaltwasser
A new analysis may give clinicians a more in-depth understanding of an individual patient’s multiple sclerosis (MS) disease course.
MS eye image
June 25th 2021

Study Offers New Tools to Differentiate Between MS, Neuromyelitis Optica Spectrum Disorder

Jared Kaltwasser
Although existing research has shown structural differences between multiple sclerosis (MS) and neuromyelitis optica spectrum disorder in following optic neuritis, the new report also covers non–optic neuritis eyes.
Doctor and patient consulting
June 22nd 2021

Early Intensive DMT Use May Prevent Greater Long-term Disability in RRMS

Maggie L. Shaw
Early intensive treatment was more efficacious at slowing disease accumulation in patients with relapsing-remitting multiple sclerosis (RRMS) vs initiating therapy with a moderate-efficacy disease-modifying treatment (DMT) prior to switching to a higher-efficacy DMT.
Paradigm Shift in MS Management
June 22nd 2021

Paradigm Shift in MS Management

Neil Minkoff, MD Maria Lopes, MD, MS Nancy Ross, PharmD, BCACP, MSCS, CSP Thomas Leist, MD Darin Okuda, MD
Experts in MS discuss the evolution in treatment options over time and the shift towards use of early high-efficacy therapy.
Graphic of brain waves in seizure
June 19th 2021

Review Finds 3% of Patients With MS Have Epilepsy, 2% Experience Seizures

Jared Kaltwasser
The report gives a more holistic picture of a highly studied by little understood issue in multiple sclerosis.
Neurons on fire
June 17th 2021

MS Wrap-up: Measuring Disease Activity in MS, MRI Guidelines Updated, and More

AJMC Staff
Here are some of the latest developments in multiple sclerosis (MS) from our sister publication, NeurologyLive®.
Patient Journey in MS
June 17th 2021

Patient Journey in MS

Neil Minkoff, MD Maria Lopes, MD, MS Nancy Ross, PharmD, BCACP, MSCS, CSP Thomas Leist, MD Darin Okuda, MD
Thomas Leist, MD describes the epidemiology of MS and the journey of patients as the disease progresses.
Overview of Multiple Sclerosis
June 17th 2021

Overview of Multiple Sclerosis

Neil Minkoff, MD Maria Lopes, MD, MS Nancy Ross, PharmD, BCACP, MSCS, CSP Thomas Leist, MD Darin Okuda, MD
A multidisciplinary panel of experts provide an overview of the progressive nature of multiple sclerosis (MS) and discuss how clinicians, payers, and pharmacists approach management of the disease.
Burdened individual
June 11th 2021

Adults With MS, Comorbidities Shoulder Significant Economic, Health Burdens

Maggie L. Shaw
The study authors hope their findings inform future interventions whose goal is to minimize the comorbidity burden of adults with multiple sclerosis (MS), thereby improving their quality of life and ultimate health outcomes.
Group of kids
June 9th 2021

Lower Risk of Relapse Seen Among UK Children With RRMS Receiving Newer DMTs

Maggie L. Shaw
Compared with their peers receiving injectable treatments for their relapsing-remitting multiple sclerosis (RRMS), children who received newer disease-modifying therapies (DMTs) had improved scores on several measures of disease progression.
News graphic
June 5th 2021

MS Wrap-up: Walking Improvement, Pregnancy in RMS, and More

AJMC Staff
Here are some of the latest developments in multiple sclerosis (MS) from our sister publication, NeurologyLive®.
Graphic of brain activity
June 3rd 2021

Analysis Yields miRNA Linked With Atrophy in Patients With MS

Jared Kaltwasser
The new study identified altered microRNA (miRNA) in gray matter lesions, which could provide a new important marker of multiple sclerosis (MS) progression.
Graphic of brain and spinal cord
May 29th 2021

Study Tracks Social Cognition, Amygdala Changes in Patients With RRMS

Jared Kaltwasser
Patient social cognition remained stable over 3 years, but its correlation with structural damage in the brain changed over time.
MS-affected nerve graphic
May 27th 2021

MS Wrap-up: World MS Day, Practice Effects on MSPT Battery, and More

Maggie L. Shaw
Here are some of the latest developments in multiple sclerosis (MS) from our sister publication, NeurologyLive®.
Study: Confirmed Disability Progression Provides Limited Predictive Value in MS
May 21st 2021

Study: Confirmed Disability Progression Provides Limited Predictive Value in MS

Jared Kaltwasser
Confirmed disability progression is often used as a study endpoint to predict progression, but a new report says its predictive value may be overblown.
Neon graphic of brain
May 19th 2021

MS Wrap-up: Research Needs in Progressive MS, AAN Annual Meeting, and More

Maggie L. Shaw
Here are some of the latest developments in multiple sclerosis (MS) from our sister publication, NeurologyLive®.
brain graphic
May 15th 2021

Study Identifies Potential Molecular Biomarker of Progressive MS

Gianna Melillo
Using data from 2 independent cohorts, researchers identified a potential molecular biomarker for progressive multiple sclerosis (MS).
Strength exercise
May 13th 2021

Metabolic Changes May Indicate Improved Clinical Outcomes in Multiple Sclerosis

Progressive resistance training was shown to positively alter several measures of disease progression in the study cohort: fatty acid, phospholipid, and sex steroid metabolism.
Teen with MS
May 7th 2021

Recent Gains for Patients With POMS Linked to Therapeutic, Disease Management Advancements

Maggie L. Shaw
Although knowledge is plentiful on disease state improvements for adult patients with multiple sclerosis (MS) following use of newer disease-modifying therapies, less is known about similar outcomes among patients with pediatric-onset MS (POMS).
Antibodies in bloodstream
May 3rd 2021

B-Cell Depletion May Indicate Reduced COVID-19 Antibody Response Among Patients With MS

Maggie L. Shaw
New research demonstrates that patients with multiple sclerosis (MS) who were asymptomatic for COVID-19 had lower antibody levels against SARS-CoV-2, its causative virus, due to having fewer B cells.
Informational chart
April 30th 2021

DMT Uptake, Prescriptions Not Fitting Disease Course Among Patients With MS

Maggie L. Shaw
Because real-world data are lacking on disease-modifying treatment (DMT) prescribing patterns for patients with multiple sclerosis (MS), a team of investigators wanted to make sure these individuals were receiving adequate care.
Tracking patients
April 26th 2021

MS Care Not So Routine During the Pandemic

Maggie L. Shaw
Risk of infection topped the list of concerns among patients with multiple sclerosis (MS) who altered their usual care routines during the COVID-19 pandemic.
<123456789
...
21>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo